Baqsimi is a nasal spray formulation of glucagon, already widely used as an injectable treatment for hypoglycaemia, which can occur when people with diabetes inadvertently take too much insulin.

Alternative dosing routes, such as rectal and intranasal (IN) routes, have been suggested as options for oral or intravenous administration. Rhinitis and pharmacological agents used for treatment ...

Glucagon is a recognised therapy for the disorder ... 2019 as a hypoglycaemia rescue therapy for diabetics. Eli Lilly's nasal spray Baqsimi was also approved in 2019 for a similar indication.

Intranasal (IN) delivery of medications is ... topical anesthetics, glucagon for hypoglycemia, and agents for epistaxis control. Many new medications, or new uses for common medications via ...

After hours: February 7 at 6:59:20 PM EST Loading Chart for AMPH ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...